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Abstract
Background: Pulmonary Langerhans-cell histiocytosis (PLCH) is a rare interstitial lung disease characterized by
clusters of Langerhans cells, organized in granulomas, in the walls of distal bronchioles. It is a diffuse lung disease
related to tobacco smoking but otherwise of unknown etiopathogenesis.
Methods: In this study we used a proteomic approach to analyze BAL protein composition of patients with PLCH
and of healthy smoker and non-smoker controls to obtain insights into the pathogenetic mechanisms of the
disease, to study the effect of cigarette smoking on susceptibility to PLCH and to identify potential new
biomarkers.
Results: Two-dimensional electrophoresis and image analysis revealed proteins that were differently expressed
(quantitatively and qualitatively) in the three groups of subjects. The proteins were identified by mass spectrometry
and have various functions (antioxidant, proinflammatory, antiprotease) and origins (plasma, locally produced, etc.).
Many, such as protease inhibitors (human serpin B3) and antioxidant proteins (glutathione peroxidase and
thioredoxin) are already linked to PLCH pathogenesis, whereas other proteins have never been associated with the
disease. Interestingly, numerous proteolytic fragments of plasma proteins (including kininogen-1 N fragments and
haptoglobin) were also identified and suggest increased proteolytic activity in this inflammatory lung disease.
Differences in protein expression were found between the three groups and confirmed by Principal Component
Analysis (PCA).
Conclusion: Analysis of BAL proteomes of PLCH patients and of smoker and non-smoker controls also proved to
be useful for researching the pathogenetic mechanisms and for identifying biomarkers of this rare diffuse lung
disease.
Introduction
Pulmonary Langerhans cell histiocytosis (PLCH) is a
rare granulomatous disorder characterized by uncon-
trolled proliferation and infiltration of CD1+ Langerhans
cells (LCs) in the lung. It has been associated with
smoking and prevalently affects young adults [1,2]. The
pathogenesis of PLCH is unclear. The bronchiolar distri-
bution of lesions suggests that an inhaled antigen, such
as cigarette smoke, may be involved, since 90% of cases
are smokers [3]. The correlation between PLCH and
smoking is corroborated by recent studies demonstrat-
ing that acute tobacco smoke inhalation determines
immediate and selective recruitment of LCs into human
airways, inducing a very early reaction of the adaptive
immune system [4-6]. Moreover, cigarette smoke pro-
motes survival signals and prolongs survival of dendritic
cells [7]. Smoke-induced alterations at lung level can
therefore induce changes in lung condition determining
a typical protein profile at bronchoalveolar and plasma
level.
Proteomics is a powerful approach that enables lung
diseases to be studied through the characterization and
identification of protein marker profiles that can high-
light specific pathological states. A proteomic approach
to the study of BAL is extremely useful for insights into
pathogenesis and identification of biomarkers [8]. There
is no literature on BAL proteomic findings in PLCH.
We therefore studied BAL protein composition in
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healthy smoker controls by a proteomic approach using
two-dimensional electrophoresis (2-DE) and mass spec-
trometry (MS) in order to obtain insights into the
pathogenesis of PLCH, to evaluate the effect of smoking
on disease progression and to discover new prognostic
biomarkers.
Materials and methods
Population
The study population consisted of five PLCH patients of
Caucasian race (3 female, mean age 33.15 ± 36.13
years), five healthy non-smokers (3 female, mean age
59.13 ± 24.2) and five healthy smokers (2 female, mean
age 43.17 ± 29.62) monitored at Siena Regional Referral
Centre for Interstitial Lung Diseases for a period of at
least four years. All patients were currently smokers
w i t ht h ee x c e p t i o no fas i n g l ep a t i e n tw h ow a sa ne x -
smoker. We analyzed exposure of our patients to envir-
onmental pollution retrospectively and interestingly,
none of the patients lived in big cities: all came from
the country or small towns with no significant exposure
to pollutants. No professional risk was found as 3/5
were office workers, another a teacher and the fifth a
cook. Diagnosis of PLCH was conducted according to
international criteria [9-11]; three patients had a diagno-
sis based on histological examination of transbronchial
biopsies showing tissue positivity for anti-CD1a and
S100 protein staining; the other two had a diagnosis
based on clinical-radiological findings and BAL features
(including CD1a positivity). All patients underwent pul-
monary function tests (PFT) and gas exchange evalua-
tion according to ERS guidelines [12]. All patients gave
their written informed consent to enrolment in the
study.
Bronchoalveolar lavage
Bronchoscopy with BAL was performed in all patients
for diagnostic reasons as previously reported [13-15].
Lymphocyte phenotype was analyzed by flow cytometry
(Facs-Calibur, Becton Dickinson) using anti -CD3,
-CD4, -CD8 and -CD1a monoclonal antibodies.
Two-Dimensional Gel Electrophoresis (2DE)
BAL samples were dialyzed against water, lyophilized
and dissolved in lysis buffer (8 M urea, 4% CHAPS, 40
mM Tris base, 65 mM dithioerythritol and trace
amounts of bromophenol blue). Protein concentration
was determined according the Bradford method [16].
2DE was carried out using the Immobiline polyacryla-
mide system, as previously described [17] on a pre-
formed immobilized nonlinear pH gradient, from pH 3
to 10, 18 cm length, from GE Healthcare (Uppsala,
Sweden). Sample load was 60 μg per strip in analytical
runs, and 1 mg per strip in preparative gels. Analytical
runs were carried out using the Ettan™ IPGphor™
system (Amersham Biosciences) at 16°C under the fol-
lowing electrical conditions: 0 V for 1 h, 30 V for 8 h,
200 V for 1 h, from 300 to 3500 V in 30 min, 3500 V
for 3 h, from 3500 to 8000 V in 30 min, 8000 V up to
a total of 80,000 Vh. Preparative strips were rehydrated
with 350 μLU R E A8M ,4 %w / vC H A P S ,1 %w / vD T E
and 2% v/v carrier ampholyte at room temperature for
12 h. Sample load was obtained by cup loading, with
the cup applied at the cathodic and anodic ends of the
strip. MS-preparative runs were obtained using the
Multiphor™ II electrophoresis system and the follow-
ing voltage steps at 16°C: 200 V for 6 h, 600 V for 1 h,
1200 V for 1 h, 3500 V for 3 h, 5000 V for 14 h. After
the first dimension run, the IPG gels were equilibrated
in 6 M urea, 2% w/v SDS, 2% w/v DTE, 30% v/v gly-
cerol and 0.05 M Tris-HCl pH 6.8 for 12 min; and for
a further 5 min in 6 M urea, 2% w/v SDS, 2.5% w/v
iodoacetamide, 30% v/v glycerol, 0.05 M Tris-HCl pH
6.8 and a trace of bromophenol blue. After the two
equilibration steps, the second dimensional separation
was performed on 9-16% SDS polyacrylamide linear
gradient gels (18 × 20 cm × 1.5 mm), and carried out
at 40 mA/gel constant current, at 9°C until the dye
f r o n tr e a c h e dt h eb o t t o mo ft h eg e l[ 1 8 ] .A n a l y t i c a l
gels were stained with ammoniacal silver nitrate
[19,20]. MS-preparative gels were stained with SYPRO
Ruby (Bio-rad headquarters, Hercules, California)
according to the manufacturer’s instructions. Bind-
silane (g methacryloxypropyltrimethoxysilane)
(LKBProdukter AB, Brommo, Sweden) was used to
attach polyacrylamide gels covalently to a glass surface
for those undergoing SYPRO Ruby staining [21].
Ammoniacal silver nitrate stained gels were then digi-
tized by a Molecular Dynamics 300S laser densit-
ometer (4000 × 5000 pixels, 12 bits/pixel; Sunnyvale,
CA, USA). Preparative gel images stained with SYPRO
Ruby were digitized with a Typhoon 9400 laser densit-
ometer (GE Healthcare). Computer-aided 2D image
analysis was carried out with the Image Master Plati-
num 7.0 computer system (GE Healthcare). Spot detec-
tion was achieved after defining and saving a set of
detection parameters, enabling filtering and smoothing
of the original gel scans to clarify spots, and removal
of vertical and horizontal streaks and speckles. The
analysis process was performed by matching all gels of
each group with a reference gel for the same condition
with the best resolution and greatest number of spots,
chosen by the user and named “master” by the soft-
ware. The three master reference gels were then
matched with each other. By this procedure, the Image
Master Platinum algorithm matched the other gels to
find qualitative and quantitative differences.
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Statistical analysis of the samples was performed using
Statistical software packages SPSS 13.0 for Windows
and Graphpad Prism 5 for Windows. Data was
expressed as mean ± standard deviation (M ± SD). For
the proteomic approach, statistical analysis of proteins
expressed differently in the three groups was carried out
using Student’s T-test, one-way ANOVA and Tukey’s
test. Only unmatched spots or spots with significantly
d i f f e r e n t% V( p<0 . 0 5b yA N O V A )w e r ec o n s i d e r e d
“differently expressed” in the three groups.
Mass Spectrometry
Protein identification was carried out by PMF on an
Ettan MALDI-TOF Pro (GE Healthcare), as previously
described [22,23]. Electrophoretic spots from SYPRO
Ruby stained gels were mechanically excised by an Ettan
Spot Picker (GE Healthcare), destained in 2.5 mM
ammonium bicarbonate and 50% acetonitrile, and dehy-
drated in acetonitrile. They were then rehydrated in
trypsin solution and digested overnight at 37°C. 0.75 μL
of each protein digest was spotted onto the MALDI tar-
get and allowed to dry. Then 0.75 μL of matrix solution
(saturated solution of CHCA in 50% v/v ACN and 0.5%
v/v TFA) was applied to the dried sample, and dried
again. After acquiring the mass of the peptide, a mass
fingerprinting search was carried out in Swiss-Prot/
TrEMBL and NCBInr databases using MASCOT
(Matrix Science Ltd., London, UK, http://www.
matrixscience.com) software available on-line. Taxon-
omy was limited to Mammalia, mass tolerance was 100
ppm, and the number of missed cleavage sites accepted
was set at one. Alkylation of cysteine by carbamido-
methylation was assumed and oxidation of methionine
was considered as a possible modification. Sequence
coverage, number of matched peptides and probability
score are shown in the tables.
Multivariate analysis
Principal Components Analysis (PCA) was performed
for the three groups to reduce proteomic data complex-
ity and to identify meaningful groups and associations
in the dataset. PCA transforms a number of correlated
variables (e.g. individual protein spot abundance levels
in each experimental sample) into a smaller number of
uncorrelated variables, called principal components. In
this study PCA was used to cluster the experimental
groups on the basis of protein spot expression in BAL
(spot maps). Percentage volumes of spots differently
expressed in the three analysis groups (PLCH versus
non-smoker controls, PLCH versus smoker controls and
non-smoker versus smoker controls) were included in
the PCA analysis, which was performed using STATIS-
TICA 7.0 software (Statsoft, Inc.). In the resulting graph,
the spot maps were plotted in two-dimensional space,
showing the principal components PC1 and PC2 that
divided the samples analyzed orthogonally according to
the two principal sources of variation in the data set.
Results
Population
Table 1 reports the clinical features, LFT and bronchoal-
veolar lavage results of the group of PLCH patients. As
expected, BAL cell profile showed eosinophilia greater
than 6%, mild neutrophilia and 8.1% [± 5.3] CD1a-posi-
tive cells. Low DLCO was evident in all patients at the
time of bronchoscopy and lung function tests revealed
obstructive pattern in 2 patients, restrictive deficit in 1
patient and a normal functional pattern in the other 2
cases.
Proteome analysis
Figure 1 shows the master gels of the three groups
(PLCH patients and smoker/non-smoker controls), cho-
sen as reference gels because of their high resolution
and large number of protein spots. An average of 1100
spots was detected in each gel across groups. When our
master gels were matched by Image Master Platinum
7.0, qualitative and quantitative protein differences were
observed. MALDI-ToF/MS identified these proteins,
including two found for the first time in BAL samples:
serpin B3 (SPB3) and plastin-2 (PLSL), which were up-
regulated in smokers versus non-smokers and down-
regulated in PLCH patients versus smokers. Among
spots expressed differently between groups, there were
modulators of immune responses (such as polymeric
immunoglobulin receptor (PIGR), immunoglobulin light
chain, Ig alpha-1 chain C region, PLSL, Ig gamma-1
chain C region, IgG K chain), proteins implicated in
antioxidant defence (thioredoxin (THIO), albumin
(ALBU), ceruloplasmin (CERU), glutathione peroxidase
Table 1 Clinical characteristics, BAL and LFT features of
our PLCH population.
NUMBER OF PATIENTS 5
AGE 33,15 ± 36,13
GENDER 2 MALE
BAL MACROPHAGES (%) 77,2 ± 15,6
BAL LYMPHOCYTES (%) 9,9 ± 19,3
BAL NEUTROPHILS (%) 4,7 ± 2,1
BAL EOSINOPHILS (%) 6,88 ± 3,4
CD1+ 8,1 ± 5,3
OBSTRUCTIVE 2
RESTRICTIVE 1
DECREASED
DLCO
5
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Page 3 of 153 (GPX3)), cell-cycle regulators (creatinine kinase B-
Type, ADP ribosylation factor-like protein 3 and
annexin A3 (ANXA3)), proteins involved in ion trans-
port (such as serotransferrin (TRFE) and hemoglobin
subunit beta) and several inflammatory proteins (includ-
ing pigment epithelium derived factor (PEDF) and apoli-
poprotein A1 (APOA1)). Alpha-1-antitrypsin (A1AT)
isoforms and SPB3 were spots with anti-protease
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Figure 1 The master gels of the three groups: PLCH patients and smoker/non-smoker controls.
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phorylase, pyruvate kinase isozymes, fibrinogen gamma
chain, alpha 1B glycoprotein and actin cytoplasmic 1
were identified. BAL proteome analysis of PLCH
patients also revealed several proteolytic fragments of
plasma proteins, such as albumin (ALBU), haptoglobin
(HPT) and kininogen-1 (KNG1). Five isoforms of alpha
1 anti-trypsin (A1AT) were differentially expressed in
BAL of the three groups.
Considering only spots constantly present in all gels of
all groups, significant qualitative variations in sensitivity
to silver staining were observed for the nine spots
(Table 2). Some of these proteins were found in healthy
controls but not in patients and others were found in
PLCH and smoker-control samples but not in those of
non-smoker controls. Fifty nine spots showed at least ±
2 times variations in percentage of relative volume (%V)
(%V = Vsingle spot/Vtotal spot). These spots were sig-
nificantly up- or down-regulated in BAL samples of
PLCH patients with respect to BAL of smoker and non-
smoker controls (p < 0.05). Tables 3, 4 and 5 list the
proteins identified from these spots with their accession
numbers, theoretical and experimental molecular
weights, pIs, Mascot search results, mean and standard
deviations, statistical p values and number of folds of
protein expression in the three groups.
Twenty-eight spots were quantitatively more abundant
in PLCH than in non-smoker and/or smoker control
samples. The proteins of 24/28 spots were identified
and are listed in Table 3. KNG1 fragment N-terminal (p
< 0.00001) and an isoform of A1AT were strongly up-
regulated in PLCH patients with respect to controls
(Table 3). Figure 2 shows the expression of KNG1 N-
terminal fragment (an inflammatory protein never stu-
died in PLCH) in patients and controls. The percentage
volume of two spots identified as PEDF (a protease inhi-
bitor) were particularly elevated in patients than con-
trols (p < 0.001) (Figure 3). Another protein involved in
cell proliferation, motility, invasiveness and signaling
pathways, up-regulated in PLCH with respect to con-
trols (p < 0.01) and potentially involved in pathogenesis,
is ANXA3 (Figure 4).
Thirteen spots were down-regulated in PLCH com-
p a r e dt on o n - s m o k e ra n d / o rs m o k e rc o n t r o l s( T a b l e4 ) .
The protein spots PIGR, THIO and PLSL were down-
regulated in PLCH compared to controls and are of par-
ticular interest because of their specific functions and
potential implication in the disease. Figures 5 and 6
show the trend of expression of PIGR, THIO percentage
volumes in patients and controls.
Seventeen spots were also significantly differently
expressed between healthy smoker and non-smoker
controls, as well as between controls and PLCH patients;
10/17 were identified (table 5). Table 5 is divided in two
parts: the first includes protein spots significantly down-
regulated in non-smoker compared to smoker controls;
the second includes spots up-regulated in non-smoker
compared to smoker controls. Among the spots up-
regulated in smokers, SPB3 is a protein with anti-pro-
tease function identified de novo in BAL; there is no lit-
erature on SPB3 and smoke-induced lung damage.
Multivariate analysis
Multivariate statistical analysis by PCA was used to
examine global trends in protein expression in BAL of
PLCH patients and non-smoker and smoker controls.
These samples were grouped according to the variance
of their protein expression (%V) and their spatial distri-
bution is shown in Figure 7. The first principal compo-
nent (PC1) explained 49.94% of the variance and the
second (PC2) explained a further 20.06%. PCA showed
that PLCH and control samples clustered in distinct
groups along the PC2 axis. In the control cluster, there
were two other distinct groups very close to each other:
those of non-smoker and smoker controls.
Discussion
BAL protein expression analyzed by 2DE in a population
of PLCH patients was compared with that of control
samples. Bioinformatics analysis identified a wide range
of spots expressed differently in BAL of PLCH patients
with respect to BAL of healthy controls. The effect of
cigarette smoking on the expression of some proteins
was also evaluated, comparing BAL protein patterns of
smoker and non-smoker controls.
Population
The clinical, immunological and functional features of
our PLCH patients indicated prevalently obstructive
lung function deficit, increased BAL CD1a+ cells
together with neutrophilia and eosinophilia, in line with
the literature [1,2].
2DE
Proteomic analysis of BAL revealed 59 spots expressed
with quantitative differences and 9 spots expressed with
qualitative differences in BAL of PLCH patients with
respect to controls. The proteins identified from these
spots are involved in specific biological mechanisms
(inflammation, immunity, oxidative stress, protease-anti-
protease balance, cell proliferation, fibrosis) potentially
implicated in the pathogenesis of PLCH. Some of these
proteins need to be studied in detail, as they could be
useful diagnostic or prognostic biomarkers.
Two proteins never described in BAL were identified
de novo: serpin B3 and plastin 2. The first, up-regulated
in smokers and higher (with borderline significance p =
0.05) in PLCH than controls, is a member of the family
Landi et al. Journal of Clinical Bioinformatics 2011, 1:31
http://www.jclinbioinformatics.com/content/1/1/31
Page 5 of 15Table 2 Proteins identified in BAL qualitatively differently expressed in PLCH patients than controls.
Spot
letter
Protein name AC Theoretical pI/
Mr (KDa)
Experimental pI/
Mr (KDa)
Mascot search result Mean %V ± SD × 10
-4 1-way ANOVA p
value
Localization
No. of matched
peptide
Sequence
coverage
Score nsc sc PLCH
a Serum albumin,
fragment c-term
P02768 5.92 6.3 5 11 64 67±68* 175±56*
¥ 0
¥ 0,0005 Plasma
71317 47485
B Serum albumin,
fragment c-term
P02768 5.92 5.9 10 20 128 28±39* 125±69*
¥ 0
¥ 0,002 Plasma
71317 41761
D Alcohol dehydrogenase P14550 6.32 6.44 15 52 223 90±101* 396±159*
¥ 0
¥ 0,0002 Cytoplasm
36892 37399
e Annexin A1 P04083 6.57 6.57 12 42 179 22±35* 326±265*
¥ 0
¥ 0,009 Cytoplasm-
Nucleus
38918 33339
g Glutathione peroxidase
3
P22352 8.26 5.48 9 34 121 108±40* 386±229*
¥ 0
¥ 0,001 Plasma
25765 17509
h Beta-2-glycoprotein 1 P02749 8.34 5.89 6 28 91 0* 997±277*
¥ 319
±253
¥
3,27E-05 Plasma
39584 56152
i Serum albumin,
fragment c-term
P02768 5.92 6.25 8 11 78 0
§ 61±97
¥ 381
±254
¥§
0,005 Plasma
71317 14042
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5Table 3 List of identified proteins with their accession numbers, theoretical and experimental molecular weights, pIs,
No. of
spot
Protein name AC Theoretical
pI/Mr
(KDa)
Experimental
pI/Mr (KDa)
Mascot search result Mean %V ± SD × 10-4 1-way
ANOVA p
value
Folds in Localization
No. of
matched
peptide
Sequence
coverage
(%)
Score nsc sc PLCH Nsc-
sc
Nsc-
PLCH
Sc-
PLCH
PLCH >
nsc and/or
sc
1 Kininogen-1,
fragment N-
term
P01042 6.34 4.95 11 18 118 543±105
§ 225±214
¥ 5393±1864
¥§ 8.97E-06 2.41 9.93
§ 23.96
¥ Secreted-
extracellular
space
72996 61092
2 Ig alpha-1
chain C region
P01876 6.08 5.98 8 25 116 879±788
§ 206±207
¥ 3179±1685
¥§ 0,002 4.26 3.61
§ 15.43
¥ Secreted
38486 60221
3 Pigment
epithelium
P36955 5.97 5.61 8 24 111 405±176
§ 281±87
¥ 1230±693
¥§ 0,007 1.44 3.03
§ 4.37
¥ Secreted
46484 49075
4 Pigment
epithelium
P36955 5.97 5.69 8 21 114 326±211
§ 307±182
¥ 767±260
¥§ 0,009 1.06 2.35
§ 2.49
¥ Secreted
46484 49222
5 Haptoglobin,
fragment c-
term.
P00738 6.13 5.26 12 31 114 446±69
§ 432±180
¥ 2062±1186
¥§ 0,003 1.03 4.62
§ 4.77
¥ Plasma
45861 40355
6 Creatine kinase
B-type
P12277 5.34 5.31 7 26 108 267±146
§ 161±93
¥ 749±306
¥§ 0,001 1.65 2.80
§ 4.65
¥ Cytoplasm
42902 41841
7 Annexin A3 P12429 5.63 5.59 8 32 111 158±159
§ 127±54
¥ 530±318
¥§ 0,017 1.24 3.35
§ 4.17
¥ Cytoplasm
36524 31681
8 Alpha-1 anti
tripsin
P01009 5.37 4.84 15 46 212 1491±1178
§ 299±413
¥ 5425±817
¥§ 1,79E-06 4.98 3.63
§ 18.14
¥ Plasma
46878 53626
9 Alpha-1 anti
tripsin
P01009 5.37 4.8 8 27 107 495 ± 979
§ 28 ± 64
¥ 2644 ± 1473
¥§ 0,003 17.6 5.34
§ 94.42
¥ Plasma
46878 54359
10 Ceruloplasmin P00450 5.44 5.1 11 13 134 135±118
§ 154±149
¥ 496±121
¥§ 0,001 1.14 3.67
§ 3.22
¥ Plasma
122983 131973
11 Alpha-1-
antitrypsin
P01009 5.37 4.96 13 41 175 288±221
§ 423±204
¥ 1359±551
¥§ 0,001 1.46 4.71
§ 3.21
¥ Plasma
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5Table 3 List of identified proteins with their accession numbers, theoretical and experimental molecular weights, pIs, (Continued)
46878 58032
12 Serotransferrin P02787 6.81 6.05 8 11 102 415±322
§ 162±219
¥ 2655±1223
¥§ 0,0003 2.56 6.39
§ 16.38
¥ Plasma
79280 60048
13 Serotransferrin P02787 6.81 6 11 19 112 623±170
§ 672±576
¥ 3255±2316
¥§ 0,016 1.07 5.22
§ 4.84
¥ Plasma
79280 80091
14 Pyruvate kinase
isozymes
P14618 7.96 6.47 11 28 105 276±236
§ 642±290
¥ 1391±596
¥§ 0,003 2.32 5.03
§ 2.16
¥ Cytoplasm-
Nucleus
58470 58174
15 Apolipoprotein
A-I
P02647 5.56 5.03 8 26 99 179±103
§ 276±197
¥ 924±371
¥§ 0,0009 1.54 5.16
§ 3.34
¥ Plasma
30759 23065
16 Hemoglobin
subunit beta
P68871 6.75 6.77 11 77 155 109 ± 131
§ 328 ±
123
¥
650 ± 233
¥§ 0,001 3 5.96
§ 1.98
¥ Blood
16102 11120
17 Ceruloplasmin P00450 5.44 5.13 15 18 123 259±183
§ 180±179
¥ 564±99
¥§ 0,005 1.43 2.17
§ 3.13
¥ Plasma
122983 130654
18 Alpha-1-
antitrypsin
P01009 5.37 4.7 11 32 143 277±290 93±77
¥ 599±288
¥ 0,018 2.97 2.16 6.44
¥ Plasma
46878 50566
19 Actin,
cytoplasmic 1
P60709 5.29 5.07 9 28 107 867±437 320±272
¥ 1071±348
¥ 0,016 2.7 1.23 3.34
¥ Cytoskeleton
42052 40664
20 Ceruloplasmin P00450 5.44 5.16 10 11 101 306±223 201±151
¥ 537±137
¥ 0,02 1.52 1.75 2.67
¥ Plasma
122983 130000
21 Serotransferrin P02787 6.81 6.07 16 22 166 1085±228
§ 1831
±559
4471±2939
§ 0,022 1.68 4.12
§ 2.44 Plasma
79280 80.091
22 Serotransferrin P02787 6.81 6.14 18 23 188 2376±300
§ 3235
±879
4969±1743
§ 0,01 1.36 2.09
§ 1.53 Plasma
79280 79397
23 Fibrinogen
gamma chain
P02679 5.37 5.52 10 28 133 511±354
§ 766±671 2649±2055
§ 0,039 1.49 5.18
§ 3.45 Plasma
52106 53481
24 Alpha-1-
antitrypsin
P01009 5.37 5.29 8 27 121 197±222
§ 641±651 1938±1200
§ 0,01 3.25 9.83
§ 3.02
¥ Plasma
46878 54009
Mascot search results, mean and standard deviations, statistical p values and number of folds of protein expression in the three groups. Statistical significant differences between smoking controls (sc) and no-
smoking controls (nsc) are visualized by *, statistical differences between smoking controls and Pulmonary Langerhans cell Histiocytosis (PLCH) are visualized by
¥and significant differences occurring between no-
smoking controls and Pulmonary Langerhans cell Histiocytosis are shown by
§. The proteins quantitatively more abundant in PLCH than in non-smoker and/or smoker control samples are reported in table 3.
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5Table 4 Proteins down-regulated in PLCH compared to non-smoker and/or smoker controls.
No.
of
spot
Protein name AC Theoretical
pI/Mr
(KDa)
Experimental
pI/Mr (KDa)
Mascot search result Mean %V ± SD × 10
-4 1-way
ANOVA p
value
Folds in Localization
No. of
matched
peptide
Sequence
coverage
(%)
Score nsc sc PLCH Nsc-
sc
Nsc-
PLCH
Sc-
PLCH
PLCH < nsc and/or sc
25 Polymeric
immunoglobulin
receptor
P01833 5.58 5.14 10 18 129 2901±438
§ 3037±1038
¥ 911±694
¥§ 1.31E-03 1.04 3.18
§ 3.33
¥ Cell membrane
84429 87377
26 Thioredoxin P10599 4.82 4.67 6 40 82 665±113 1492±819
¥ 230±235
¥ 0,005 2.24 2.89 6.48
¥ Cytoplasm-
Secreted
12015 12098
27 Plastin-2 P13796 5.2 5.19 10 21 102 873±355 1272±320
¥ 453±386
¥ 0,01 1.45 1.92 2.80
¥ Cytoplasm-
Cytoskeleton-Cell
junktion
70815 61983
28 Serum albumin P02768 5.92 6.04 8 14 92 1830±647 2980±827
¥ 1239±1363
¥ 0,04 1.62 1.47 2.40
¥ Plasma
71317 57513
29 Serum albumin,
fragment
P02768 5.92 6.09 6 9 74 278±137 405±224
¥ 124±83
¥ 0,049 1.45 2.24 3.26
¥ Plasma
N-term 71317 31059
30 ADP-ribosylation
factor-like protein
3
P36405 6.74 7.37 6 52 107 305±161 621±331
¥ 142±49
¥ 0,012 2.03 2.14 4.37
¥ Membrane
20614 21404
31 Alpha-1B-
glycoprotein
P04217 5.58 5.16 8 22 109 1370±414
§ 1163±443 663±83
§ 0,022 1.17 2.06
§ 1.75 Plasma
54809 75685
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5Table 5 Proteins differently expressed between smoker and no-smoker controls and between PLCH patients and controls.
No.
of
spot
Protein name AC Theoretical
pI/Mr
(KDa)
Experimental
pI/Mr (KDa)
Mascot search result Mean %V ± SD × 10
-4 1-way
ANOVA p
value
Folds in Localization
No. of
matched
peptide
Sequence
coverage
(%)
Score nsc sc PLCH Nsc-
sc
Nsc-
PLCH
Sc-
PLCH
PLCH < nsc and/or sc
25 Polymeric
immunoglobulin
receptor
P01833 5.58 5.14 10 18 129 2901±438
§ 3037±1038
¥ 911±694
¥§ 1.31E-03 1.04 3.18
§ 3.33
¥ Cell membrane
84429 87377
26 Thioredoxin P10599 4.82 4.67 6 40 82 665±113 1492±819
¥ 230±235
¥ 0,005 2.24 2.89 6.48
¥ Cytoplasm-
Secreted
12015 12098
27 Plastin-2 P13796 5.2 5.19 10 21 102 873±355 1272±320
¥ 453±386
¥ 0,01 1.45 1.92 2.80
¥ Cytoplasm-
Cytoskeleton-Cell
junktion
70815 61983
28 Serum albumin P02768 5.92 6.04 8 14 92 1830±647 2980±827
¥ 1239±1363
¥ 0,04 1.62 1.47 2.40
¥ Plasma
71317 57513
29 Serum albumin,
fragment
P02768 5.92 6.09 6 9 74 278±137 405±224
¥ 124±83
¥ 0,049 1.45 2.24 3.26
¥ Plasma
N-term 71317 31059
30 ADP-ribosylation
factor-like protein
3
P36405 6.74 7.37 6 52 107 305±161 621±331
¥ 142±49
¥ 0,012 2.03 2.14 4.37
¥ Membrane
20614 21404
31 Alpha-1B-
glycoprotein
P04217 5.58 5.16 8 22 109 1370±414
§ 1163±443 663±83
§ 0,022 1.17 2.06
§ 1.75 Plasma
54809 75685
This table is divided in two parts: the first part includes protein spots significantly down-regulated in non-smoker compared to smoker controls; the second part includes spots up-regulated in non-smoker than
smoker controls.
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5of protease inhibitors involved in cell survival and asso-
ciated with lung cancer [24]. The second protein, plastin
2, member of a large family of actin filament cross-lin-
kers, was down-regulated in PLCH patients with respect
to smoker controls. Plastin 2 triggers immune response,
cell migration, proliferation and cell-adhesion [25] and
its role in actin cytoskeleton rearrangement and T-cell
activation is crucial. Another function of plastin 2 is
protection against TNF-cytotoxicity [26]. As cigarette
smoke may induce production of tumor necrosis factor-
alpha (TNF-a) by alveolar macrophages [27], up-regula-
tion of PLSL2 in BAL of smokers may have a protective
role against this pro-inflammatory cytokine. Interestingly
i no u rP L C Hp a t i e n t st h i sm e c h a n i s mw a sd o w n -
regulated.
The results of our proteome analysis of PLCH BAL
suggested the involvement of some immunoinflammatory
pathways in its pathogenesis, which remains obscure. For
example, the profibrotic effect of certain proteins could
play a key role in development of PLCH. Pigment epithe-
lium derived factor (PEDF) is a protein known to be
involved in fibrogenesis. In our study PEDF was signifi-
cantly higher in BAL samples of PLCH patients than
smoker and no-smoker controls. This protein is an endo-
genous anti-angiogenic factor [28] implicated in a variety
of diseases in which angiogenesis is critical, such as non-
small cell lung cancer and IPF [28-31]. Immunohisto-
chemical studies on IPF located PEDF in fibroblastic foci
and areas of active matrix synthesis, where vascular den-
sity is low [31]. Recent research indicates that PEDF can
be regarded as a TGF b1-mediated profibrotic agent [32].
These findings suggest that PEDF may be implicated in
the regulation of vascular and fibrotic damage occurring
in PLCH.
The role of angiogenesis in the pathophysiology of
PLCH is controversial. Little data is available about neo-
vascularization in PLCH [33]. Senechal et al. recently
Figure 2 KNG1 N-terminal fragment percentage of volume (%
V) in BAL samples of PLCH patients and controls.
Figure 3 The percentage of volume (%V) of two spots
identified as PEDF in BAL samples of patients with PLCH
respect to controls.
Figure 4 Annexin A3 (ANXA3) %V in BAL of PLCH patients
smoker controls and no-smoker controls.
Figure 5 Polymeric Immunoglobulin Receptor (PIGR) %V in
BAL of PLCH patients smoker controls and no-smoker controls.
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Page 11 of 15reported that PLCH lesions were sites of neoangiogen-
esis and tissue remodelling [34], whereas an immunohis-
tochemical analysis by Zielonka et al. indicated that
PLCH granulomas are connected with areas of extensive
neoangiogenesis in which interleukin 1 alpha (IL-1a)
and TNF-a are over-expressed [35]. In contrast to these
lung tissue results, it has also been found that serum
from PLCH patients inhibited angiogenesis [35]. Our
study demonstrated that several proteins implicated in
vascular remodelling were up-regulated in BAL of
PLCH patients versus controls. Annexin A3, for exam-
ple, is a calcium- and phospholipid-binding protein
involved in angiogenesis as well as in cell proliferation,
motility, invasiveness and signaling pathways [36,37].
This protein, up-regulated in PLCH patients with
respect to controls, is reported in the literature to be
over-expressed in lung adenocarcinoma associated with
metastases [38]. Its multiple functions in PLCH patho-
genesis warrants further investigation.
Our study suggests an imbalance between protease
and anti-protease with consequent proteolytic-mediated
lung damage potentially involved in the pathogenesis of
PLCH, confirming previous observations [39]. In fact,
we found a great abundance of proteolytic fragments of
plasma proteins in BAL of PLCH patients, suggesting
increased proteolytic activity. In particular kininogen 1
and haptoglobin proteolytic fragments were more highly
expressed in BAL of PLCH patients than BAL of con-
trols. An increased anti-proteolytic activity was found
expressed by the significant increase of five isoforms of
alpha 1-antitrypsin in BAL of PLCH patients with
respect to smoker and/or non-smoker controls [39].
Several studies have analyzed smoke-induced oxidative
stress in normal subjects but little data is available on
the potential role of oxidation in PLCH [40].
Glutathione peroxidase 3 is an antioxidant protein with
ap r o t e c t i v er o l ea g a i n s tc i garette smoke-induced lung
inflammation [41]. It protects cells and enzymes against
oxidative damage by catalyzing the reduction of hydro-
gen peroxide, lipid peroxides and organic hydroperoxide
by glutathione [41]. Interestingly, in our research this
protein was significantly higher in smoker than non-
smoker controls but almost absent in BAL of PLCH
patients (who were all smokers). It should be investi-
gated if there is a defective production or/and an
increased consumption in PLCH, as it has been demon-
strated that oxidative stress is generally higher in PLCH
patients than smoker controls [40]. Thioredoxin was
another antioxidant protein down-regulated in BAL of
PLCH patients with respect to smoker controls. It plays
ap r o t e c t i v er o l ea g a i n s tc i garette smoke-induced lung
oxidative damage [42,43] and reacts against reactive oxy-
gen species (ROS) and other free radicals which are con-
sidered causative factors of smoke-related diseases in
humans [44]. Thioredoxin counteracts Th2-driven air-
way inflammation by suppressing local production of
macrophage migration inhibitory factor (MIF), irrespec-
tive of systemic Th1/Th2 immune modulation [45].
Interestingly, THIO is noto n l yd o w n - r e g u l a t e di n
PLCH but also in idiopathic pulmonary fibrosis (IPF)
[46].
Polymeric immunoglobulin receptor is a transmem-
brane protein involved in mucosal immunity (mediating
transcytosis of polymeric IgA and IgM) [47,48]. This
protein was significantly down-regulated in BAL of
PLCH patients with respect to controls. Stress, smoking
and inflammation can modulate PIGR production
through TNF-a and interleukin-1b (IL1b), allowing
translation of systemic inflammatory signals into muco-
sal immune responses [49], this mechanism seems to be
compromised in PLCH. Recruitment of Langerhans cells
in the lungs during exposure to smoke may induce T-
helper 1 and T-helper 17 responses in CD4 T cells.
Th17 cells produce interleukin 17 (IL17) that enhances
secretion of CCL20, a chemoattractant for dendritic
cells and matrix metalloproteinase 12 from lung macro-
phages [50,51]. Th17 and Th1 also promote PIGR activ-
ity by production of IL-17 and IL-1 [47]; this
mechanism creates feedback that induces inflammatory
cell recruitment and lung destruction [47]. The large
quantity of Th17 in smoke-exposed lungs may therefore
explain the high levels of PIGR required to amplify the
mucosal immune response in BAL of smokers. This pro-
tein showed a different pattern in PLCH than in healthy
smokers being decreased in PLCH, although PLCH
patients were all smokers, suggesting a possible pathoge-
netic (not smoking related) role. PIGR, Th1 and Th17
immune responses should be deeply investigated in
PLCH.
Figure 6 T h i o r e d o x i n( T H I O )i nB A Ls a m p l e so fP L C Hp a t i e n t s
compared with smoker controls and no-smoker controls.
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PLCH pathogenesis could be annexin A1, a cell media-
tor of the anti-inflammatory action of glucocorticoid
[52] that inhibits neutrophil extravasation [53]. The
inflammatory environment induced by smoking is asso-
ciated with increased epithelial permeability to neutro-
phils, macrophages and myeloid dendritic cells [4,42,54].
Complete loss of ANXA1 found in BAL of PLCH
patients may lead to reduced response to steroids, over-
recruitment of neutrophils in the lungs and loss of nega-
tive feedback for extravasation.
PCA
In this study, PCA and analysis of the patterns of pro-
teins differently expressed enabled us to distinguish our
BAL samples into three groups (PLCH patients and
P
C
2
:
 
2
0
,
0
6
%
PC1: 49,94%
Figure 7 PCA analysis. The symbols represent the PC of the maps of spots expressed differently in BAL of PLCH patients and controls. The red
ellipse shows the PC distribution of spot maps of smoker controls, the green ellipse shows that of non-smoker controls and the blue ellipse that
of PLCH patients.
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Page 13 of 15smoker and non-smoker controls), which was one of our
aims. Very high reproducibility was observed between
BAL samples and distinct expression patterns in the
three groups. Conducting multivariate analysis by PCA,
we distinguished three groups in relation to the PC2 y-
axis, and observed that non-smoker and smoker controls
were both in the upper part of the graph, close together.
This suggested that their patterns of protein expression
were more similar to each other than to the PLCH
group, despite the fact that they, too, were clearly sepa-
rated, not only suggesting similar characteristics but also
that exposure to cigarette smoke induced a modest
change in the pattern of protein expression in BAL
(smokers versus non-smokers). The position of the
PLCH group on the opposite side of PC2 with respect
to controls confirmed that the disease group had a pro-
tein profile different from that found in a condition of
health (Figure 7).
In conclusion, proteomic analysis of BAL from
patients with PLCH and smoker and non-smoker con-
trols distinguished proteins up- and down-regulated in
the disease differently expressed from smoker controls
and than disease-related. Among these proteins there
were PIGR and thioredoxin. The observation that cer-
tain proteins, over-expressed in PLCH patients, are also
elevated in IPF suggests common pathways for the
development of lung fibrosis [55]. Our proteomic study
also indicates that oxidative stress, proteolysis and
angiogenetic factors may be involved in the pathogenesis
of PLCH, although further studies are needed also to
assess the impact of other agents including pollution.
Our future aim will be to further investigate the func-
tions of the proteins of interest, their potential modifica-
tions induced by local damage (i.e. oxidation and
proteolysis) and to validate the present results on a lar-
ger patients population.
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